Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Retained Earnings (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Retained Earnings readings, the most recent being -$728.0 million for Q1 2026.

  • Quarterly Retained Earnings fell 348425.36% to -$728.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$728.0 million through Mar 2026, down 348425.36% year-over-year, with the annual reading at $786000.0 for FY2025, 100.14% up from the prior year.
  • Retained Earnings hit -$728.0 million in Q1 2026 for Oric Pharmaceuticals, down from $786000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $786000.0 in Q4 2025 and bottomed at -$728.0 million in Q1 2026.
  • Average Retained Earnings over 5 years is -$247.5 million, with a median of -$268.3 million recorded in 2022.
  • The largest annual shift saw Retained Earnings plummeted 1578141.18% in 2022 before it skyrocketed 229.01% in 2025.
  • Oric Pharmaceuticals' Retained Earnings stood at -$1.3 million in 2022, then skyrocketed by 119.98% to $258000.0 in 2023, then plummeted by 218229.46% to -$562.8 million in 2024, then surged by 100.14% to $786000.0 in 2025, then crashed by 92720.87% to -$728.0 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Retained Earnings are -$728.0 million (Q1 2026), $786000.0 (Q4 2025), and -$661.7 million (Q3 2025).